TY - JOUR
T1 - Obesity, immunomodulation and chronic kidney disease
AU - Börgeson, Emma
AU - Sharma, Kumar
N1 - Funding Information:
Work in Prof Sharma's laboratory is supported by VA MERIT Award and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Awards, specifically U01 DK060995, DP3 DK094352-01 and DK083142. Dr Börgeson is a recipient of Marie Curie international outgoing fellowship.
PY - 2013
Y1 - 2013
N2 - Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.
AB - Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.
UR - http://www.scopus.com/inward/record.url?scp=84885956835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885956835&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2013.05.011
DO - 10.1016/j.coph.2013.05.011
M3 - Review article
C2 - 23751262
AN - SCOPUS:84885956835
SN - 1471-4892
VL - 13
SP - 618
EP - 624
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
IS - 4
ER -